Pediatric pulmonary hypertension

Debra Boyer; Jessica E. Pittman; Fei Jamie Dy; Ambalavanan Arunachalam; Raed A. Dweik; Steven H. Abman; Kevin C. Wilson; Carey C. Thomson

doi:10.1513/AnnalsATS.201602-110CME

Pediatric pulmonary hypertension

Debra Boyer^*, Jessica E. Pittman, Fei Jamie Dy, Ambalavanan Arunachalam, Raed A. Dweik, Steven H. Abman, Kevin C. Wilson, Carey C. Thomson

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	967-969
Number of pages	3
Journal	Annals of the American Thoracic Society
Volume	13
Issue number	6
DOIs	https://doi.org/10.1513/AnnalsATS.201602-110CME
State	Published - Jun 2016
Externally published	Yes

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1513/AnnalsATS.201602-110CME

Cite this

@article{0d6ade8f76b34e22ad5ad180c4009b14,

title = "Pediatric pulmonary hypertension",

author = "Debra Boyer and Pittman, {Jessica E.} and Dy, {Fei Jamie} and Ambalavanan Arunachalam and Dweik, {Raed A.} and Abman, {Steven H.} and Wilson, {Kevin C.} and Thomson, {Carey C.}",

note = "Funding Information: The University of Colorado School of Medicine has received consulting fees for Dr. Ivy from Actelion, Bayer, Gilead, Eli Lilly, Pfizer, and United Therapeutics. The University Medical Center Groningen has received consulting fees for Dr. Berger from Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, and Pfizer. Dr. Berger has performed consultancies for Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, Pfizer, and United Therapeutics. Dr. Bonnet has received lecture and consulting honoraria from Actelion, Eli Lilly, Pfizer, and Bayer. Dr. Fleming has served as a consultant to Actelion and Pfizer. Dr. Haworth has received consulting fees from GlaxoSmithKline. Dr. Rosenzweig has received research grant support from Actelion, Gilead, GlaxoSmithKline, Eli Lilly, Bayer, and United Therapeutics ; and consulting honoraria from United Therapeutics and Actelion. The University of California has received consulting fees for Dr. Steinhorn from Ikaria and United Therapeutics, and she has served as an unpaid consultant to Actelion. Dr. Beghetti has served as an advisory board member for Actelion, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, and Pfizer; has received grants from Actelion and Bayer ; has receiving lecture fees from Actelion, Bayer, and Pfizer; has developed educational materials for Actelion and Pfizer; and has receiving consulting fees from Actelion, Bayer, GlaxoSmithKline, Pfizer, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2016",

month = jun,

doi = "10.1513/AnnalsATS.201602-110CME",

language = "English (US)",

volume = "13",

pages = "967--969",

journal = "Annals of the American Thoracic Society",

issn = "2325-6621",

publisher = "American Thoracic Society",

number = "6",

}

TY - JOUR

T1 - Pediatric pulmonary hypertension

AU - Boyer, Debra

AU - Pittman, Jessica E.

AU - Dy, Fei Jamie

AU - Arunachalam, Ambalavanan

AU - Dweik, Raed A.

AU - Abman, Steven H.

AU - Wilson, Kevin C.

AU - Thomson, Carey C.

N1 - Funding Information: The University of Colorado School of Medicine has received consulting fees for Dr. Ivy from Actelion, Bayer, Gilead, Eli Lilly, Pfizer, and United Therapeutics. The University Medical Center Groningen has received consulting fees for Dr. Berger from Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, and Pfizer. Dr. Berger has performed consultancies for Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, Pfizer, and United Therapeutics. Dr. Bonnet has received lecture and consulting honoraria from Actelion, Eli Lilly, Pfizer, and Bayer. Dr. Fleming has served as a consultant to Actelion and Pfizer. Dr. Haworth has received consulting fees from GlaxoSmithKline. Dr. Rosenzweig has received research grant support from Actelion, Gilead, GlaxoSmithKline, Eli Lilly, Bayer, and United Therapeutics ; and consulting honoraria from United Therapeutics and Actelion. The University of California has received consulting fees for Dr. Steinhorn from Ikaria and United Therapeutics, and she has served as an unpaid consultant to Actelion. Dr. Beghetti has served as an advisory board member for Actelion, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, and Pfizer; has received grants from Actelion and Bayer ; has receiving lecture fees from Actelion, Bayer, and Pfizer; has developed educational materials for Actelion and Pfizer; and has receiving consulting fees from Actelion, Bayer, GlaxoSmithKline, Pfizer, and Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2016/6

Y1 - 2016/6

UR - http://www.scopus.com/inward/record.url?scp=84989284868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989284868&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201602-110CME

DO - 10.1513/AnnalsATS.201602-110CME

M3 - Review article

C2 - 27295157

AN - SCOPUS:84989284868

SN - 2325-6621

VL - 13

SP - 967

EP - 969

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

IS - 6

ER -

Pediatric pulmonary hypertension

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this